Completed PHASE3 INTERVENTIONAL 1-arm NCT00911261

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain

Sponsor: Endo Pharmaceuticals

Conditions Cancer Chronic Pain Neuropathic Pain

Interventions Oxymorphone Extended Release

Updated 6 times since 2017 Last updated: Feb 12, 2010 Started: Aug 31, 2003 Primary completion: Mar 31, 2005 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00911261, this PHASE3 trial focuses on Cancer and Chronic Pain and remains completed. Sponsored by Endo Pharmaceuticals, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endo Pharmaceuticals

Data source: Endo Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.